When analyzing data, you will sometimes find one value that is far from the others. Such a value is called an outlier. When you encounter an outlier, you may be tempted to delete it from the analysis. Assuming that the data point is not attributable to obvious experimental mistakes, do you keep it or delete it?
The authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
The authors describe the qualification of an assay with applications for investigating functional comparability of an originator and biosimilar drug.
Do you have to worry about FDA releasing confidential data? Apparently so.
The "due diligence framework" is an efficient process. But efficient is not the same as quick and easy. There are no shortcuts. The framework minimizes resource commitments and disruptions to ongoing programs and helps each side learn what it needs to know. In six steps, it converts the typical due diligence root canal into a painless filling.
The authors present scale-up from a 5-L fermentor to a 50-L pilot-scale using the criterion of constant power consumption per unit liquid volume.
Understanding opportunities and challenges across all major phases of development.
This article discusses the evaluation of a novel single-use fluidized bed centrifuge for harvesting of antibodies.
MAb polishing using salt tolerant interaction membrane chromatography.
Growth in infrastructure and process-development capabilities will be required to support the biologics market.
The complex structure of ADCs necessitates different analytical strategies than those for either small molecules or unconjugated monoclonal antibodies.
Evaluating the assembly design process, manufacture, and use helps mitigate risk.
The authors present scale-up from a 5-L fermentor to a 50-L pilot-scale using the criterion of constant power consumption per unit liquid volume.
Understanding opportunities and challenges across all major phases of development.
Key business considerations when developing biosimilar products virtually.
Understanding opportunities and challenges across all major phases of development.
The author highlights novel strains and methods that have recently been shown to express multidisulfide bonded proteins.
Understanding opportunities and challenges across all major phases of development.
MIT survey results address product and site characteristics that statistically correlate with quality performance.
When developing a strategy for using technology in biopharmaceutical manufacturing, include the interaction between automation and business systems and the roles they play in enhancing quality assurance and compliance.